The Women's Health Initiative represents a large population-based sample of 161,000 postmenopausal US women. These women have been well-characterized in terms of demographics, diverse exposures, quality of life assessments and incidence of chronic diseases, including over 20,000 incident invasive cancers over a mean 12 years of follow-up. A biorepository maintains >5 million vials of serum, plasma and DNA, and over 93,000 women continue in active follow-up. WHI investigators seek to enhance opportunities for cancer survivorship studies, particularly those that recognize the import of molecular heterogeneity of tumors, by addressing two key limitations in the existing program. Specifically, we propose to;1) collect information on cancer treatment, clinical outcomes (recurrence) and patient reported outcomes in women diagnosed with selected cancers (breast, colorectal, endometrial, lung, and ovarian cancers, lymphoma, leukemia, and melanoma, projected n=21,882) during WHI participation using Medicare linkages or direct medical record abstraction;and 2) collect paraffin-embedded tumor tissue from selected cancers (colorectal and ovarian cancers, melanoma, lymphoma, and breast and lung cancer subtypes, projected n=5,900). We will collect treatment and outcome data via linkage to Medicare datasets for cost efficiencies, whenever possible, and will pursue and evaluate methods to collect these data through access to other administrative databases. By enhancing the WHI database with cancer treatment and recurrence data, WHI will be a valuable resource to examine the effects of cancer diagnosis and treatment on overall health and quality of life in an aging cohort-one that represents the fastest growing population, bears the great cancer burden but has been under-represented in randomized trials. By supplementing the specimen repository with tumor specimens, the WHI Program will be able to support """"""""up-to-date"""""""" phenotyping of cancers and contribute to our understanding of the molecular basis of cancer, its treatment and survival. We want to begin soon to ensure that a large and representative resource can be realized, because tumor tissue and records for cases diagnosed in the early period of the WHI will become increasingly difficult to obtain.
We propose to collect information on cancer treatment and recurrence so that the WHI database may be used to assess the impact of these factors on choices of cancer treatment, treatment success, and prognosis in an aging population of women. We seek to collect tumor tissue from cancer cases so that the most current laboratory techniques may be applied to help understand the molecular basis of cancer.
|Paskett, Electra D; Caan, Bette J; Johnson, Lisa et al. (2018) The Women's Health Initiative (WHI) Life and Longevity After Cancer (LILAC) Study: Description and Baseline Characteristics of Participants. Cancer Epidemiol Biomarkers Prev 27:125-137|
|Reeves, Katherine W; Pennell, Michael; Foraker, Randi E et al. (2018) Predictors of vasomotor symptoms among breast cancer survivors. J Cancer Surviv 12:379-387|
|Simon, Michael S; Beebe-Dimmer, Jennifer L; Hastert, Theresa A et al. (2018) Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative. Cancer 124:1798-1807|
|Cespedes Feliciano, Elizabeth M; Prentice, Ross L; Aragaki, Aaron K et al. (2017) Methodological considerations for disentangling a risk factor's influence on disease incidence versus postdiagnosis survival: The example of obesity and breast and colorectal cancer mortality in the Women's Health Initiative. Int J Cancer 141:2281-2290|
|Chlebowski, Rowan T; Aragaki, Aaron K; Anderson, Garnet L et al. (2017) Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. J Clin Oncol 35:2919-2926|
|Kroenke, Candyce H; Chubak, Jessica; Johnson, Lisa et al. (2016) Enhancing Breast Cancer Recurrence Algorithms Through Selective Use of Medical Record Data. J Natl Cancer Inst 108:|
|Denlinger, Crystal S; Ligibel, Jennifer A; Are, Madhuri et al. (2014) Survivorship: immunizations and prevention of infections, version 2.2014. J Natl Compr Canc Netw 12:1098-111|
|Denlinger, Crystal S; Carlson, Robert W; Are, Madhuri et al. (2014) Survivorship: introduction and definition. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 12:34-45|
|Denlinger, Crystal S; Ligibel, Jennifer A; Are, Madhuri et al. (2014) Survivorship: fatigue, version 1.2014. J Natl Compr Canc Netw 12:876-87|
|Denlinger, Crystal S; Ligibel, Jennifer A; Are, Madhuri et al. (2014) Survivorship: nutrition and weight management, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 12:1396-406|
Showing the most recent 10 out of 17 publications